Real-time Estimate
Cboe BZX
12:31:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
47.96
USD
|
-1.07%
|
|
-4.54%
|
+21.08%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,635
|
1,369
|
1,323
|
1,191
|
1,749
|
-
|
-
|
Enterprise Value (EV)
1 |
1,635
|
1,369
|
1,323
|
860
|
1,447
|
1,628
|
1,623
|
P/E ratio
|
-24.1
x
|
-23.2
x
|
-11.6
x
|
-7.65
x
|
-9.86
x
|
-9.23
x
|
-9.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
68.1
x
|
-
|
7,889
x
|
337
x
|
280
x
|
51.6
x
|
EV / Revenue
|
-
|
68.1
x
|
-
|
5,696
x
|
279
x
|
260
x
|
47.9
x
|
EV / EBITDA
|
-
|
-
|
-
|
-5.09
x
|
-7.8
x
|
-7.48
x
|
-6.98
x
|
EV / FCF
|
-44
x
|
-21.7
x
|
-18.5
x
|
-6.77
x
|
-8.16
x
|
-9.05
x
|
-8.65
x
|
FCF Yield
|
-2.27%
|
-4.61%
|
-5.39%
|
-14.8%
|
-12.3%
|
-11.1%
|
-11.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,178
|
23,399
|
27,543
|
29,959
|
36,084
|
-
|
-
|
Reference price
2 |
70.54
|
58.51
|
48.02
|
39.76
|
48.48
|
48.48
|
48.48
|
Announcement Date
|
3/25/21
|
3/9/22
|
3/3/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
10
|
-
|
20.1
|
-
|
0.151
|
5.186
|
6.252
|
33.87
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-169.1
|
-185.5
|
-217.6
|
-232.4
|
EBIT
1 |
-
|
-46.66
|
-56.37
|
-114.8
|
-169.9
|
-191.8
|
-211.1
|
-206.5
|
Operating Margin
|
-
|
-
|
-280.46%
|
-
|
-112,543.71%
|
-3,698.09%
|
-3,376.93%
|
-609.54%
|
Earnings before Tax (EBT)
1 |
-
|
-45.53
|
-56.73
|
-104.7
|
-153
|
-180.6
|
-199.7
|
-192.1
|
Net income
1 |
-
|
-45.36
|
-58.74
|
-104.7
|
-153
|
-177.3
|
-205.2
|
-205
|
Net margin
|
-
|
-
|
-292.26%
|
-
|
-101,319.21%
|
-3,418.63%
|
-3,282.75%
|
-605.3%
|
EPS
2 |
-2.800
|
-2.930
|
-2.520
|
-4.150
|
-5.200
|
-4.914
|
-5.250
|
-5.021
|
Free Cash Flow
1 |
-
|
-37.19
|
-63.17
|
-71.3
|
-127
|
-177.5
|
-179.9
|
-187.5
|
FCF margin
|
-
|
-
|
-314.29%
|
-
|
-84,087.42%
|
-3,421.81%
|
-2,876.77%
|
-553.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
3/25/21
|
3/9/22
|
3/3/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
20
|
-
|
-
|
-
|
-
|
-
|
-
|
0.00001
|
0.143
|
0.083
|
-
|
-
|
5.652
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.866
|
-24.13
|
-30.73
|
-27.98
|
-31.96
|
-38.87
|
-41.34
|
-43.28
|
-46.46
|
-48.48
|
-48.37
|
-49.3
|
-44.53
|
-49.77
|
-50.5
|
Operating Margin
|
-24.33%
|
-
|
-
|
-
|
-
|
-
|
-
|
-432,800,000%
|
-32,486.01%
|
-58,413.25%
|
-
|
-
|
-787.91%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.941
|
-24.19
|
-27.27
|
-23.51
|
-29.72
|
-35.8
|
-37.5
|
-39.44
|
-40.24
|
-43.11
|
-45.36
|
-46.67
|
-43.24
|
-47.31
|
-48.98
|
Net income
1 |
-6.94
|
-24.19
|
-27.27
|
-23.51
|
-29.72
|
-35.8
|
-37.5
|
-39.44
|
-40.24
|
-43.11
|
-44.92
|
-46.36
|
-41.11
|
-47.31
|
-48.98
|
Net margin
|
-34.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-394,400,000%
|
-28,141.96%
|
-51,944.58%
|
-
|
-
|
-727.48%
|
-
|
-
|
EPS
2 |
-0.3000
|
-1.010
|
-1.130
|
-0.9200
|
-1.090
|
-1.260
|
-1.270
|
-1.330
|
-1.340
|
-1.210
|
-1.248
|
-1.283
|
-1.173
|
-1.255
|
-1.295
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/3/23
|
5/4/23
|
8/7/23
|
11/6/23
|
2/28/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
331
|
302
|
122
|
127
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-37.2
|
-63.2
|
-71.3
|
-127
|
-177
|
-180
|
-188
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-50.2%
|
-44.8%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-4.230
|
-3.210
|
-3.840
|
-
|
Capex
1 |
-
|
0.29
|
1.02
|
1.24
|
2.46
|
1.63
|
3.42
|
3.75
|
Capex / Sales
|
-
|
-
|
5.09%
|
-
|
1,631.79%
|
31.35%
|
54.66%
|
11.07%
|
Announcement Date
|
2/27/20
|
3/25/21
|
3/9/22
|
3/3/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
48.48
USD Average target price
88.78
USD Spread / Average Target +83.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +21.83% | 1.75B | | +10.26% | 118B | | +10.80% | 106B | | -9.00% | 23.4B | | -1.95% | 22.1B | | -9.61% | 18.34B | | -41.70% | 16.59B | | -15.34% | 15.97B | | +6.49% | 14.03B | | +19.57% | 11.67B |
Bio Therapeutic Drugs
|